ArticleBritish journal of cancer2010
The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Dyslipidaemias in cancer patients.European heart journal · 2026Review
- 5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge.BMJ case reports · 2023Article
- Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database.International journal of clinical pharmacy · 2022Observational
- Ketogenic diets consumed during radio-chemotherapy have beneficial effects on quality of life and metabolic health in patients with rectal cancer.European journal of nutrition · 2022Article
- CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer.Cancer science · 2021Article
- Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Article
- Effect of lipid metabolism disorder on liver function in patients with malignant tumors after chemotherapy: a case-control study.Lipids in health and disease · 2019Article
- Capecitabine-induced hypertriglyceridemia: a rare but clinically relevant treatment-related adverse event.Journal of gastrointestinal oncology · 2018Article
- Ameliorative Effect of Caffeic Acid on Capecitabine-Induced Hepatic and Renal Dysfunction: Involvement of the Antioxidant Defence System.Medicines (Basel, Switzerland) · 2017Article
- Effect of onion flavonoids on colorectal cancer with hyperlipidemia: an in vivo study.OncoTargets and therapy · 2014Article
- Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.Diagnostic pathology · 2013Article
- Severe hypertriglyceridaemia during treatment with capecitabine.British journal of cancer · 2011Article
- Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report.Case reports in oncologyArticle
- Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report.Case reports in oncologyArticle
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCapecitabine is known to rarely cause raised serum triglycerides (TG). In our centre, several patients receiving capecitabine developed raised TG levels corresponding to the 'very high risk' category for potentially serious acute pancreatitis.
methodsA fasting blood lipid screening protocol was introduced into clinical practice for patients receiving capecitabine. Patients with TGs >5 mmol l(-1) were treated and followed up. An 18-month prospective audit was performed to establish the incidence and severity of capecitabine-induced hypertriglyceridaemia (CIHT).
resultsA total of 304 patients received capecitabine for colorectal cancer between January 2008 and June 2009. Of these, 212 patients (70%) were screened and 8 (3.7%) developed clinically significant hypertriglyceridaemia requiring lipid-lowering therapy. Two of the eight patients had diabetes and one had pre-existing dyslipidaemia. One suffered cerebral infarction during chemotherapy. There were no cases of acute pancreatitis. Follow-up showed that serum TGs safely and rapidly returned to normal with appropriate treatment without discontinuation of capecitabine.
conclusionsThis is the first prospective study evaluating CIHT. These results suggest that it should be classed as a 'common' undesired effect of capecitabine. Despite this, the incidence does not justify routine screening in all patients. Targeted screening in those with diabetes or pre-existing hyperlipidaemia is recommended, together with adoption of a clear management policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.